CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by StockNews.com
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a note issued to investors on Friday. Several other equities research analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a note issued to investors on Friday. Several other equities research analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in […]
